(Q34281892)

1 August 2017

1 reference

title

Hydroxyurea for sickle cell disease (English)

1 reference

1 August 2017

0 references

1 reference

S Davies

1

1 reference

1 August 2017

A Olujohungbe

series ordinal

2

1 reference

1 August 2017

publication date

1 January 2001

1 reference

Cochrane Database of Systematic Reviews

1 August 2017

published in

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

CD002202

1 reference

Hydroxyurea and sickle cell anemia: effect on quality of life

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and geographical location

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Blood transfusion in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Pain, quality of life, and coping in sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Patterns of mortality in sickle cell disease in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Mortality in sickle cell disease. Life expectancy and risk factors for early death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Hematologic Responses of Patients with Sickle Cell Disease to Treatment with Hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Early deaths in Jamaican children with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Management of sickle cell disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Cellular effects of hydroxyurea in Hb SC disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Management of sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Management of patients with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Minimal doses of hydroxyurea for sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Pain in sickle cell disease. Rates and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002202

10.1002/14651858.CD002202

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference